UBS Maintains Buy on Medpace Hldgs, Raises Price Target to $480
Portfolio Pulse from Benzinga Newsdesk
UBS analyst John Sourbeer maintains a Buy rating on Medpace Holdings (MEDP) and raises the price target from $452 to $480.
March 08, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS maintains a Buy rating on Medpace Holdings and increases the price target from $452 to $480.
The upgrade in price target by a reputable analyst like John Sourbeer from UBS is a strong positive signal for Medpace Holdings. It suggests confidence in the company's future performance and growth potential, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100